Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases
AssigneeAstraZeneca AB
InventorsPeter GREASLEY, Christine AHLSTRÖM, Stanko SKRTIC, Robert MENZIES
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatment of certain endothelin related diseases.
Claims22
1-9. (canceled)
A method of treating chronic kidney disease in a human patient, the method comprising administering to the patient in need thereof, a combination of zibotentan, N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide,
- or a pharmaceutically acceptable salt thereof, and dapagliflozin.
A method of reducing the risk of eGFR decline in a human patient with chronic kidney disease, the method comprising administering to the patient in need thereof, a combination of zibotentan, N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide,
- or a pharmaceutically acceptable salt thereof, and dapagliflozin.
A method of reducing the risk of fluid retention decline in a human patient with chronic kidney disease, the method comprising administering to the patient in need thereof, a combination of zibotentan, N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide,
- or a pharmaceutically acceptable salt thereof, and dapagliflozin.
Dependencies are inferred from the claim text.